Physician profile
Waris Waris
NPI 1891807822
$9,504.02
in general payments reported to CMS, 2019-2025
43 companies · $1,309 in 2025
The $1,309 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,690 · 2020: $467 · 2021: $920 · 2022: $1,908 · 2023: $1,476 · 2024: $1,733 · 2025: $1,309.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,946 · Education: $572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,945.63 |
| Education | $572.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,613.24 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,428.32 | 2019-2025 | Opdivo, Eliquis, Opdualag |
| Pfizer INC. | $803.39 | 2019-2025 | |
| Astellas Pharma US INC | $600.36 | 2019-2025 | Padcev, Vyloy, Xospata |
| Merck Sharp & Dohme LLC | $567.44 | 2019-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Celgene Corporation | $566.44 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Daiichi Sankyo INC. | $481.73 | 2021-2025 | Enhertu, Datroway, Injectafer |
| Incyte Corporation | $451.85 | 2019-2025 | Jakafi, Pemazyre, Monjuvi |
| Amgen INC. | $362.72 | 2019-2025 | Lumakras, Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $290.59 | 2019-2025 | Imfinzi |
| Abbvie INC. | $161.83 | 2024-2025 | |
| Eisai INC. | $160.99 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $153.08 | 2021-2025 | Zepzelca |
| Array Biopharma INC | $147.69 | 2021-2025 | Braftovi, Xalkori, Lorbrena |
| Genzyme Corporation | $129.56 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waris Waris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.